Granulocyte maturation and the chromosome deletion 17p- in primary myelodysplastic syndrome

Acta Haematologica
B Pedersen, G Kerndrup

Abstract

Recent molecular biological investigations have shown that genetic information on the short arm of chromosome 17 is frequently deleted or inactivated in acute myeloid leukaemias and a number of solid tumours. In earlier studies we have found clonal occurrence of a 17p deletion (17p-) in patients with refractory anaemia. In the present study we investigated the time patterns of 17p- and morphological characters of bone marrow cells in 14 myelodysplastic patients with clonal 17p- who have been reinvestigated within 3- to 6-month intervals for 15-56 (median 37) months. We found that the 17p- frequency increases significantly with time. Further, the deletion is positively correlated with bone marrow myeloblast frequencies and negatively with those of maturing granulocytes (myelocytes and later forms). These results suggest that 17p- interferes with and delays granulocyte maturation. Inactivation or deletion of genetic material in 17p in myelodysplastic syndrome, acute myeloid leukaemia, and a wide variety of solid tumours further suggests that genes present on 17p may have a central position in malignant transformation of cells in a number of different tissues.

Citations

Oct 15, 1994·Cancer Genetics and Cytogenetics·J M HawkinsL M Secker-Walker
Nov 7, 2002·Cancer Genetics and Cytogenetics·Crisoula PatsourisLynda J Campbell
Sep 13, 2006·Cancer Genetics and Cytogenetics·Carlos A TiradoPhilip Mowrey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.